Masimo O3®'s delta hemoglobin parameters have received FDA clearance for cerebral and somatic applications and all patient ...

Masimo (Nasdaq: MASI) announced today that it received FDA 510(k) clearance for expanded indications for its O3 regional ...

The pulse oximeter maker is now fully operational after a spring cyberattack and increased its 2025 profit forecast, but ...

Medical technology company Masimo has been facing off with Apple in court since 2020, and while Masimo has scored some wins, ...

Apple will bring back the blood oxygen measurement feature to some of its watch models via a software update after receiving ...

For nearly two years, Apple Watch users in the United States lived without one of the most popular health features: blood ...

Masimo (MASI) announced the FDA 510(k) clearance of expanded indications for the delta hemoglobin parameters provided with O3 Regional Oximetry.

Apple, Masimo, and most importantly users all suffered from this bizarre legal wrangle. How did it get this far?

Masimo ( ($MASI) ) has provided an announcement. On August 18, 2025, William Jellison resigned from the Board of Directors of Masimo Corporation, ...

Medtech company Masimo announced it had received FDA De Novo clearance for Opioid Halo, the company's opioid overdose alert system. The monitoring system aims to prevent overdose by alerting family ...

Masimo, best known for its successful patent litigation over the Apple Watch, was initially targeted by Politan last year due to what the activist viewed as bad management, a lack of independent ...

For over three years now, Apple has been entrenched in a messy legal battle over a single feature on the Apple Watch — and Apple’s opponent, medical device maker Masimo, seems confident it can ...